Benefit of early treatment in inflammatory polyarthritis patients with anti-cyclic citrullinated peptide antibodies versus those without antibodies

Farragher, Tracey M., Lunt, Mark, Plant, Darren, Bunn, Diane K., Barton, Anne and Symmons, Deborah P. M. (2010) Benefit of early treatment in inflammatory polyarthritis patients with anti-cyclic citrullinated peptide antibodies versus those without antibodies. Arthritis Care & Research, 62 (5). pp. 664-675. ISSN 2151-4658

Full text not available from this repository.

Abstract

Objective To compare the clinical utility of anti–cyclic citrullinated peptide (anti-CCP) antibodies and rheumatoid factor (RF) testing in predicting both functional outcome and response to treatment in early inflammatory polyarthritis (IP) patients. Methods A total of 916 IP subjects from a primary care incidence registry (1990–1994) had anti-CCP antibody and RF status determined at baseline. Mean change in Health Assessment Questionnaire (HAQ) score between baseline and 5 years was compared by antibody status. The effect of treatment with disease-modifying antirheumatic drugs and/or steroids over 5 years, early (

Item Type:	Article
Faculty \ School:	Faculty of Medicine and Health Sciences > Norwich Medical School
UEA Research Groups:	Faculty of Medicine and Health Sciences > Research Groups > Health Promotion Faculty of Social Sciences > Research Centres > Water Security Research Centre Faculty of Medicine and Health Sciences > Research Centres > Lifespan Health
Depositing User:	Rhiannon Harvey
Date Deposited:	07 Mar 2012 11:57
Last Modified:	19 Oct 2023 00:33
URI:	https://ueaeprints.uea.ac.uk/id/eprint/38005
DOI:	10.1002/acr.20207

Actions (login required)

View Item